Aktis Oncology, Inc. (AKTS) — Stock Valuation & Research

Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target…

AKTS key statistics

Price$14.58
Market cap$783.73M
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
52-week range13.96-34.19
Beta0.45

Explore AKTS's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.